DOCSLIB.ORG

Symptom Control Medication & the Dying Person

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Symptom Control Medication & the Dying Person SYMPTOM CONTROL MEDICATION & THE DYING PERSON LITERATURE REVIEW, AUDIT RESULTS & NEW STANDARDS & GUIDELINES 27TH NOVEMBER 2014 SYMPTOM CONTROL MEDICATION & THE DYING PERSON GUIDELINE DEVELOPMENT GROUP RUTH CLARK MOIRA WATSON DR AVERIL FOUNTAIN DR AMARA NWOSU PHILIP GREEN CHRISTINE RILEY DEBORAH JONES DR CLAIRE ROBINSON DR ANDREW KHODABUKUS SESSION OUTLINE • Patient, Carer and Public Involvement • Literature Review • Existing Standards & Audit Results POWERPOINT • Updated StandardsPRESENTATION & Guidelines JULY 2012 V1.0 PROVENANCE • 2006 – initial guidelines produced • 6th March 2014 – Review meeting of CMPCNAG, majority quorate vote to review guidelines by e-Vote • Meetings of membership of Symptom Control Medication & the Dying Person Guideline Development Group POWERPOINT – 29th April 2014 – 27th May 2014 PRESENTATION th – 24 July 2014 JULY 2012 – 2nd September 2014 – 3rd October 2014 V1.0 – 7th November 2014 POWERPOINT PATIENT, CARERPRESENTATION AND PUBLIC INVOLVEMENTJULY 2012 V1.0 PATIENT, CARER & PUBLIC INVOLVEMENT • PCPI representative Christine Riley – Experience of family members dying including her sister – Involved in review of our proposal and perspectives of issues pertinent to PCPI POWERPOINT PRESENTATION JULY 2012 V1.0 PATIENT, CARER & PUBLIC INVOLVEMENT THE ROLE OF MEDICATION • Medications use is ‘part and parcel’ of management dying. • What the types of medications used are less important to PCPI • What is more important is that there is a plan in place that these would addressPOWERPOINT symptoms to make the patient comfortable and that what the medications were forPRESENTATION – which symptom groupsJULY 2012 were being addressed. is communicated well with V1.0 the family. PATIENT, CARER & PUBLIC INVOLVEMENT EXPERIENCE • Some families are distressed by the dying phase – they have no experience of it – no accurate POWERPOINT representation on the media of whatPRESENTATION it is actually like. JULY 2012 V1.0 PATIENT, CARER & PUBLIC INVOLVEMENT AN EXAMPLE • Respiratory tract secretions – many families are distressed by this as no- one told them about this. • Therefore, if discussing use (or potential use) of medications for secretions, this mustPOWERPOINT include: – a discussion withPRESENTATION the family about what secretions are – and how they willJULY be 2012 managed. V1.0 PATIENT, CARER & PUBLIC INVOLVEMENT RECOMMENDATIONS 1 • Compassion by the clinical team is important. • Guidelines about communication and the link to informing family about discussion of the dyingPOWERPOINT phase can be included in the standards and guidelines. PRESENTATION JULY 2012 V1.0 PATIENT, CARER & PUBLIC INVOLVEMENT RECOMMENDATIONS 2 • Dissemination of findings to public and patient groups was a positive thing. • Suggested ways that this could be facilitated, such as: – newsletters and talking/promotionPOWERPOINT of audit(s) at charity hospice events PRESENTATION – giving the public the opportunity to JULY 2012 participate/contribute in these. V1.0 CLAIRE ROBINSONPOWERPOINT AND AMARA NWOSU LITERATUREPRESENTATION REVIEW JULY 2012 V1.0 QUESTION “What is the evidence for the use of medications to effectively control symptoms (pain, dyspnoea, pyrexia, N&V, agitation and secretions) in adult dying patients?” POWERPOINT PRESENTATION JULY 2012 V1.0 LITERATURE REVIEW Participants Adult humans in the dying phase (last hours to days of life) Intervention Medications used for symptom control Comparator - Control - Alternative management POWERPOINT- No treatment - Comparisons with other PRESENTATIONmedications Outcome Good symptom control JULY 2012 V1.0 SEARCH STRATEGY • Pubmed • SCOPUS • CINALH • Cochrane database • Hand search(referencePOWERPOINT lists) PRESENTATION JULY 2012 V1.0 SEARCH STRATEGY 1. (((((("Seizures"[Mesh] OR ("Psychomotor Agitation/analysis"[Mesh] OR "Psychomotor Agitation/diagnosis"[Mesh] OR "Psychomotor Agitation/drug therapy"[Mesh] OR "Psychomotor Agitation/prevention and control"[Mesh] OR "Psychomotor Agitation/therapy"[Mesh])) 2. OR ("Fever/analysis"[Mesh] OR "Fever/classification"[Mesh] OR "Fever/drug therapy"[Mesh] OR "Fever/therapy"[Mesh])) 3. OR "Pain Management"[Mesh]) 4. OR ("Dyspnea/analysis"[Mesh] OR "Dyspnea/classification"[Mesh] OR "Dyspnea/drug therapy"[Mesh] OR "Dyspnea/prevention and control"[Mesh] OR "Dyspnea/therapy"[Mesh])) 5. OR ((("respiratory tract secretions"[All Fields] OR "tracheobronchial secretions"[All Fields]) OR "bronchial secretions"[All Fields]) OR "death rattle"[All Fields])) 6. OR "nausea and vomiting"[All Fields]) 7. AND ((("end of life"[All Fields] OR "end of life care"[All Fields]) OR dying[All Fields]) 8. AND ((("palliative care"[AllPOWERPOINT Fields] OR "palliative medicine"[All Fields]) OR "supportive care"[All Fields]) OR ("Terminal Care/classification"[Mesh] OR "Terminal Care/nursing"[Mesh] OR "Terminal Care/prevention and control"[Mesh]PRESENTATION OR "Terminal Care/therapy"[Mesh]))) 9. AND ((Clinical Trial[ptyp] OR Comparative Study[ptyp] OR Case Reports[ptyp] OR Meta- Analysis[ptyp] OR systematic[sbJULY]) 2012 10. AND "humans"[MeSH Terms] AND English[lang]) V1.0 SELECTION CRITERIA INCLUSION CRITERIA EXCLUSION CRITERIA Aged ≥ 18 years Aged ≤ 18 years Humans Animals Specifically about the dying Not specifically about dying phase. phase. Pharmacological Non-pharmacological management of symptoms. measures. Includes a patient related No patient related outcome outcome (e.g. POWERPOINTsymptom used (e.g. prevalence control, QOL, side effects, studies). survival) or to evaluate medication intervention.PRESENTATION Interventional, JULY 2012 Case reports, review observational, retrospective, articles, editorials,V1.0 letters. prospective, Delphi. English language. Non-English. Pubmed CINALH Scopus Cochrane References (n= 71) (n= 894) (n= 98) (n= 4) (n=24) Exclusions of abstracts (n=40) Duplicates (n= 22) Review article (n=4) Scope beyond care of the dying (n=23) Articles after Articles selected Case report (n=1) duplicates removed for abstract after German (n=2) (n= 1069) titles screened Not about medications (n=2) (n= 71) Textbook (n=5) Editorial (n=1) Web resource (n=2) POWERPOINTArticles selected for full text review Exclusions full text (n=20) (n= 31) PRESENTATIONReview article (n=8) Scope beyond care of the dying JULY 2012 Studies included in (n=5) the review (n=11) Case report (n=3) V1.0 Not about medications (n=4) RESULTS Symptom Number of articles Pain 1 Dyspnoea 0 Agitation 1 Respiratory tract secretions 8 Nausea and vomiting 0 Pyrexia 0 Generic aboutPOWERPOINT use of key 1 medications in the dying PRESENTATION JULY 2012 V1.0 QUALITY ASSESSMENT • Review included both quantitative and qualitative elements • Used a multi-methods assessment tool, devised by Hawker et al • The assessment tool consists of nine areas; Rated on a four-point scale from 1 (very poor) to 4 (good). – abstract and title – introduction and aims – methods and data; sampling – data analysis – ethics and bias – results; – transferability or generalizability – implications and usefulness. • Each paper scored (maximum of 36=good, and a minimum of 9=very poor) based on the methodological rigor. The POWERPOINTmethodological quality was assessed by A.C.N and CR. • Both authors agreed on the quality assessment of all studies. • Data were stored and analysedPRESENTATION using SPSS version 21. • The methodological quality scores are ordinal in nature; consequently Spearman JULY 2012 coefficient was chosen to measure pair-wise correlation of scoring between the assessors. V1.0 QUALITY ASSESSMENT Study Agreed score Back 2001 33 • Study quality ranged between 23 and 36. Bennett 1996 28 Campbell 2013 36 • Agreement between assessors Ellershaw 2002 34 was excellent. Hugel 2006 31 Hughes 2000 23 • Spearman coefficient = 0.9, p<0.0001). Kass 2003 28 POWERPOINT Lindqvist 2013 29 Stirling 1999 26 PRESENTATION Wildiers 2002 26 JULY 2012 Wildiers 2009 36 V1.0 Respiratory Tract Secretions POWERPOINT PRESENTATION JULY 2012 V1.0 BACK ET AL 2001 • DESIGN: Cohort study • PARTICIPANTS: Patients with death rattle. States similar age, diagnosis and gender both groups • SAMPLE: N =191, [Hyoscine (N= 128) compared with Glycopyrrolate (N= 63)] • METHOD: Scoring scale - noise volume initial, 30mins post drug, 1 hr post drug, every 4 hours. First group hyoscine hydrobromide 0.4mg. Second Group Glycopyrronium 0.2mg. Scale 0 = none, 1 = audible head of bed, 2 = end of bed, 3 = 10 steps away • RESULTS: Significant. P = 0.002 30min H HBr 56% improved vs Glyco 27%. Glyco group needed 2nd injection at 30mins. 1 hr and final scores similar. • LIMITATIONS: No exclusion criteria (could there be pseudo secretions in one group?). Groups separatedPOWERPOINT in time and less participants in second round. Increased chance of data collection bias. PRESENTATION • Hyoscine HydrobromideJULY 2012 more effective for secretions at 30minutes, no overall difference. 'There is some evidence that reduction of noise relieves carer distress'. Should we consider usingV1.0 Hyoscine Hydrobromide first line for death rattle? BACK CONT “Their literature review found that glycopyrrolate has a slower onset of action than hyoscine hydrobromide at equipotent doses (0.4mg vs 0.27 = equipotent). Increased use of diamorphine, midazolam and levomepromazine in glycopyyrolate group, therefore minimal cost saving in glycopyrrolate group (average £1.53 per patient). Possibly due to less sedative and anti-emetic effects of gylcopryyolate. To prove null hypothesis that both drugs are equally efficacious in 30 bedded unit would take 12 years or multi-centre study.” POWERPOINT PRESENTATION
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Norfolk & Waveney Prescriber
    The Norfolk & Waveney Prescriber Issue 119 April 2017 For Primary and Secondary Care Health Professionals in Norfolk & Waveney In this issue: Prescribing Safety News: MHRA Drug Safety Updates 2 TAG and Commissioning News 3-4 Drugs – discontinued, shortages and prices 5-6 Drugs – supply issues 7-8 Guidance and Policy News: - National: “NICE Bites” & NICE guidance 9-10 Guidance and Policy News: - Local: Key Message Bulletins 11-12 Cost-effective Prescribing Tips: 13 Ophthalmic Special Order products Atorvastatin Hot Topic: Multimorbidity and Polypharmacy 14 Prescribing Safety: Medicines and Serotonin Syndrome 15-16 Prescribing Advice: Metformin, Finasteride, and Inhalers 17-18 New Medicines & Indications News 19 Feedback and comments on this edition to [email protected] / 01603 257035 Prescribing & Medicines Management Team – 1 NEL CSU Anglia Prescribing Safety News Main points from MHRA Drug Safety Updates February - March 2017 Articles relevant to Primary Care and Secondary Care: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) Canagliflozin may increase the risk of lower-limb amputation (mainly toes) in patients with type 2 diabetes. Evidence does not show an increased risk for dapagliflozin and empagliflozin, but the risk may be a class effect. Preventive foot care is important for all patients with diabetes. Advice for healthcare professionals: o carefully monitor patients receiving canagliflozin who have risk factors for amputation, such as poor control of diabetes and problems with
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5
    ANTICHOLINERGICS: Reference List of Drugs with Potential Anticholinergic Effects 1, 2, 3, 4, 5 J Bareham BSP © www.RxFiles.ca Aug 2021 WHENEVER POSSIBLE, AVOID DRUGS WITH MODERATE TO HIGH ANTICHOLINERGIC ACTIVITY IN OLDER ADULTS (>65 YEARS OF AGE) Low Anticholinergic Activity; Moderate/High Anticholinergic Activity -B in combo Beers Antibiotics Antiparkinsonian Cardiovascular Agents Immunosuppressants ampicillin *ALL AVAILABLE AS amantadine SYMMETREL atenolol TENORMIN azaTHIOprine IMURAN cefOXitin GENERIC benztropine mesylate COGENTIN captopril CAPOTEN cyclosporine NEORAL clindamycin bromocriptine PARLODEL chlorthalidone GENERIC ONLY hydrocortisone CORTEF gentamicin (Oint & Sol’n NIHB covered) carbidopa/levodopa SINEMET digoxin LANOXIN, TOLOXIN methylprednisolone MEDROL piperacillin entacapone COMTAN dilTIAZem CARDIZEM, TIAZAC prednisone WINPRED dipyridamole PERSANTINE, ethopropazine PARSITAN vancomycin phenelzine NARDIL AGGRENOX disopyramide RYTHMODAN Muscle Relaxants pramipexole MIRAPEX Antidepressants baclofen LIORESAL ( on intrathecal only) procyclidine KEMADRIN furosemide LASIX amitriptyline ELAVIL cyclobenzaprine FLEXERIL selegiline ELDEPRYL hydrALAZINE APRESOLINE clomiPRAMINE ANAFRANIL isosorbide ISORDIL methocarbamol ROBAXIN OTC trihexyphenidyl ARTANE desipramine NORPRAMIN metoprolol LOPRESOR orphenadrine NORFLEX OTC doxepin >6mg SINEQUAN Antipsychotics NIFEdipine ADALAT tiZANidine ZANAFLEX A imipramine TOFRANIL quiNIDine GENERIC ONLY C ARIPiprazole ABILIFY & MAINTENA
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Effect of Diazepam and Hyoscine Butylbromide on Response to Secretin and Cholecystokinin-Pancreozymin in Man
    Gut: first published as 10.1136/gut.17.5.351 on 1 May 1976. Downloaded from Gut, 1976, 17, 351-353 Effect of diazepam and hyoscine butylbromide on response to secretin and cholecystokinin-pancreozymin in man J. H. B. SAUNDERS, GUYA MASOERO, AND K. G. WORMSLEY' From the Department of Therapeutics, University of Dundee, Dundee SUMMARY Ten subjects received secretin and cholecystokinin or, in duplicate tests, the two hor- mones together with either diazepam or diazepam plus hyoscine butylbromide in order to determine whether these drugs, which are often used during retrograde endoscopic cannulation ofthe pancreatic duct, affect pancreatic and biliary secretion in response to the hormones. Diazepam with hyoscine butylbromide reduced the secretion of trypsin into the duodenum and delayed the appearance of both trypsin and bilirubin in duodenal aspirate. These effects must be taken into account when interpreting pancreatic and biliary responses measured during direct cannulation of the pancreatic duct. Endoscopic retrograde cannulation of the pancreatic vents in the antrum. Secretin (1 clinical unit/kg-h) duct has recently been used to measure pancreatic and cholecystokinin-pancreozymin (1 Ivy unit/ function by collecting the pancreatic juice directly kg-h) were administered for 45 minutes by continuous from the pancreatic duct during stimulation with intravenous infusion in 0 15 mol/1 sodium chloride. hormones et The exogenous (Cotton al., 1974; Gregg hormones had been purchased from the GIH http://gut.bmj.com/ et al., 1975; Robberecht et
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • ACG Clinical Guideline: Management of Irritable Bowel Syndrome
    CLINICAL GUIDELINES 17 ACG Clinical Guideline: Management of Irritable Bowel Syndrome Brian E. Lacy, PhD, MD, FACG1, Mark Pimentel, MD, FACG2, Darren M. Brenner, MD, FACG3, William D. Chey, MD, FACG4, 5 6 7 02/05/2021 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8K2+Ya6H515kE= by http://journals.lww.com/ajg from Downloaded Laurie A. Keefer, PhD , Millie D. Long, MDMPH, FACG (GRADE Methodologist) and Baha Moshiree, MD, MSc, FACG Downloaded Irritable bowel syndrome (IBS) is a highly prevalent, chronic disorder that significantly reduces patients’ quality of life. Advances in diagnostic testing and in therapeutic options for patients with IBS led to the development of this first-ever from http://journals.lww.com/ajg American College of Gastroenterology clinical guideline for the management of IBS using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Twenty-five clinically important questions were assessed after a comprehensive literature search; 9 questions focused on diagnostic testing; 16 questions focused on therapeutic options. Consensus was obtained using a modified Delphi approach, and based on GRADE methodology, we endorse the by following: We suggest that a positive diagnostic strategy as compared to a diagnostic strategy of exclusion be used to improve BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8K2+Ya6H515kE= time to initiating appropriate therapy. We suggest that serologic testing be performed to rule out celiac disease in patients with IBS and diarrhea symptoms. We suggest that fecal calprotectin be checked in patients with suspected IBS and diarrhea symptoms to rule out inflammatory bowel disease. We recommend a limited trial of a low fermentable oligosaccharides, disacchardies, monosaccharides, polyols (FODMAP) diet in patients with IBS to improve global symptoms.
    [Show full text]
  • Dose-Response Relationships of Intravenous Hyoscine Butylbromide and Atropine Sulphate on Heart Rate in Healthy Volunteers S.L
    Br. J. clin. Pharmac. (1983), 16, 623-626 DOSE-RESPONSE RELATIONSHIPS OF INTRAVENOUS HYOSCINE BUTYLBROMIDE AND ATROPINE SULPHATE ON HEART RATE IN HEALTHY VOLUNTEERS S.L. GRAINGER & S.E. SMITH Department of Pharmacology, St Thomas's Hospital Medical School, London SE1 7EH 1 Heart-rate responses to intravenous hyoscine butylbromide, atropine and physiological saline in cumulative dosage regimens have been recorded in six healthy subjects. 2 Atropine sulphate induced bradycardia at low, and tachycardia at higher, dose levels whereas hyoscine butylbromide caused only tachycardia but with a flatter dose-response relationship. 3 Exact potency ratios could not be calculated because of the differing dose-response curves. However, an approximate estimate from a comparison of equiactive doses at the upper part of the curve yielded a value less than one half that obtained from the drugs' affinity constants in guinea-pig ileum. 4 The findings suggest that, in addition to its action as a muscarinic antagonist, hyoscine butylbromide is a ganglion blocker in man as it is in animals. Keywords hyoscine atropine heart rate dose-response Introduction Methods Hyoscine butylbromide is a quaternary derivative of Six healthy volunteers (3M, 3F) aged 28-40 years hyoscine which has been widely used for its spasmo- took part in the investigation. Each subject was studied lytic effect on gastrointestinal, biliary and ureteric on four occasions, separated by at least 4 days. muscle. When administered intravenously its action is Following a light breakfast, the subject rested supine brief40 mg doses producing effects which disappear and an intravenous cannula was placed in an ante- largel by 20 min.
    [Show full text]
  • Adult Irritable Bowel Syndrome (IBS) IBS Prevalence – 10-20%.Symptoms Often Noticeable 20-30Yrs
    Adult Irritable Bowel Syndrome (IBS) IBS Prevalence – 10-20%.Symptoms often noticeable 20-30yrs. Make a positiv e diagnosis based on symptoms rather than exhaustive investigations History Absolute Red Flags - Refer Urgently: Consider in anyone with a history of: Abdominal, pelvic or rectal masses Abdominal pain/discomfort eased by defecation or associated with altered stool form or frequency and at least 2 of:- Ascites Unexplained increased urinary urgency Bloating, distension, tension or hardness >40 years jaundice or unexplained weight loss Change in stool passage – straining, urgency, incomplete evacuation Bristol Sto ol Ch art (can be useful) and abdominal pain >50 years with unexplained rectal bleeding Symptoms worse with eating >60 years with iron deficiency anaemia or Passage of mucus change in bowel habit or weight loss and one Other features such as lethargy, nausea, backache and bladder symptoms are of: change in bowel habit/back pain/ abdominal pain/nausea/vomiting/new- onset common in people with IBS and may be used to support the diagnosis. Use Rom e Self-fill Q uestion naire diabetes Consider Urgent Referral Inv estigations Examination – Abdominal + rectal +/- pelvic examination Sy stemically unwell Consider arranging the following inv estigations to exclude an alternative diagnosis - Nocturnal symptoms Strong f amily history of bowel or ovarian or breast or Full blood count (FBC), Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), stool Microscopy, culture and sensitivity (MC&S), thyroid function
    [Show full text]
  • Reclassification of Hyoscine Butylbromide for Oral Use
    Reclassification of Hyoscine butylbromide for oral use in medicines containing not more than 20 milligrams per dose (Addition of oral liquids in the current classification) Present classification: Restricted Proposed classification: Restricted AFT Pharmaceuticals Limited Level 1, Nielsen Building 129 Hurstmere Rd Takapuna, Auckland, 0622 PO Box 33-203, Takapuna, Auckland Page 1 of 16 Objective: This application seeks reclassification of hyoscine butylbromide for oral use in medicines containing not more than 20 milligrams per dose. Page 2 of 16 PART A 1. International Non-Proprietary Name of the Medicine Hyoscine butylbromide 2. Proprietary name(s) Gastrosoothe (Proposed) (hyoscine butylbromide 1 mg/mL) 3. Name of the company/organisation/individual requesting a reclassification AFT Pharmaceuticals Ltd 129 Hurstmere Road Takapuna 0622 Auckland New Zealand 4. Dose form(s) and strength(s) for which a change is sought Dose form: Oral liquid Strength: 1 mg/mL Pack size: 200 mL. 5. Proposed pack size, storage conditions and any other qualifications Proposed pack size: Bottle containing 200 mL (1 mg/mL) of hyoscine butylbromide oral liquid Storage conditions: Store below 30 °C. 6. Indications for which change is sought Indication: for the relief of muscle spasm of the gastrointestinal tract 7. Present classification of the medicine Ingredient Conditions (if any) Classification Hyoscine except when specified elsewhere in this schedule Prescription butylbromide Hyoscine for oral use in medicines containing not more than 10 milligrams per Restricted butylbromide dose form and in packs containing not more than 20 tablets or capsules; for oral use in medicines containing not more than 20 milligrams per dose form and in packs containing not more than 10 tablets or capsules for the relief of muscle spasm of the gastrointestinal tract Page 3 of 16 8.
    [Show full text]